Table 1.
Patient demographics and clinical characteristics, n (%)
|
Original data |
Matched data |
|||||
| Characteristic | PA-TACE | Surgery alone | P value | PA-TACE | Surgery alone | P value |
| Age (yr) | < 0.001 | 0.889 | ||||
| < 65 | 196 (73.0) | 281 (66.0) | 158 (83.6) | 159 (84.1) | ||
| ≥ 65 | 31 (13.7) | 145 (34.0) | 31 (16.4) | 30 (15.9) | ||
| Gender | 0.245 | 0.866 | ||||
| Male | 197 (86.8) | 355 (83.3) | 170 (89.9) | 169 (89.4) | ||
| Female | 30 (13.2) | 71 (16.7) | 19 (10.1) | 20 (10.6) | ||
| BMI | 0.074 | 0.905 | ||||
| < 23 | 97 (42.7) | 188 (44.1) | 84 (44.4) | 81 (42.9) | ||
| 23-25 | 76 (33.5) | 110 (25.8) | 57 (30.2) | 61 (32.3) | ||
| ≥ 25 | 54 (23.8) | 128 (30.0) | 48 (25.4) | 47 (24.9) | ||
| BCLC stage | 0.509 | 0.614 | ||||
| 0 | 43 (18.9) | 90 (21.1) | 38 (20.1) | 42 (22.2) | ||
| A | 184 (81.1) | 336 (78.9) | 151 (79.9) | 147 (77.8) | ||
| HBV | < 0.001 | 0.362 | ||||
| Negative | 25 (11.0) | 101 (23.7) | 22 (11.6) | 28 (14.8) | ||
| Positive | 202 (89.0) | 325 (76.3) | 167 (88.4) | 161 (85.2) | ||
| HCV | 0.282 | 0.351 | ||||
| Negative | 218 (96.0) | 402 (94.4) | 183 (96.8) | 182 (96.3) | ||
| Positive | 3 (1.4) | 3 (0.7) | 0 (0) | 2 (1.1) | ||
| Unknown | 6 (2.6) | 21 (4.9) | 6 (3.2) | 5 (2.6) | ||
| Cirrhosis | 0.067 | 0.678 | ||||
| No | 114 (50.2) | 182 (42.7) | 83 (43.9) | 79 (41.8) | ||
| Yes | 113 (49.8) | 224 (57.3) | 106 (56.1) | 110 (58.2) | ||
| Family history | 0.605 | 0.876 | ||||
| No | 200 (88.1) | 381 (89.4) | 166 (87.8) | 165 (87.3) | ||
| Yes | 27 (11.9) | 45 (10.6) | 23 (12.2) | 24 (12.7) | ||
| MVI | 0.006 | 0.884 | ||||
| No | 187 (82.4) | 383 (89.9) | 161 (85.2) | 162 (85.7) | ||
| Yes | 40 (17.6) | 43 (10.1) | 28 (14.8) | 27 (14.3) | ||
| AFP (ng/mL) | < 0.001 | 1.000 | ||||
| ≤ 200 | 96 (42.3) | 252 (59.2) | 96 (50.8) | 96 (50.8) | ||
| > 200 | 131 (57.7) | 174 (40.8) | 93 (49.2) | 93 (49.2) | ||
| ALBI grade | 0.001 | 0.678 | ||||
| 1 | 129 (56.8) | 223 (52.3) | 104 (55.0) | 108 (57.1) | ||
| 2 | 92 (40.5) | 203 (47.7) | 85 (45.0) | 81 (42.9) | ||
| 3 | 6 (2.6) | 0 (0) | - | - | ||
| NLR | 0.986 | 0.918 | ||||
| ≤ Median | 116 (51.1) | 218 (51.2) | 86 (45.5) | 85 (45.0) | ||
| > Median | 111 (48.9) | 208 (48.8) | 103 (54.5) | 104 (55.0) | ||
| Ferritin (ng/mL) | 0.196 | 0.914 | ||||
| ≤ 400 | 147 (64.8) | 297 (69.7) | 125 (66.1) | 124 (65.6) | ||
| > 400 | 80 (35.2) | 129 (30.3) | 64 (33.9) | 65 (34.4) | ||
| FHR | 0.095 | 0.918 | ||||
| ≤ Median | 114 (50.2) | 243 (57.0) | 98 (51.9) | 97 (51.3) | ||
| > Median | 113 (49.8) | 183 (43.0) | 91 (48.1) | 92 (48.7) | ||
| CRP (mg/L) | 0.089 | 0.341 | ||||
| ≤ 5 | 176 (77.5) | 304 (71.4) | 138 (73.0) | 146 (77.2) | ||
| > 5 | 51 (22.5) | 122 (28.6) | 51 (27.0) | 43 (22.8) | ||
| Times | - | - | ||||
| 1 | 166 (73.1) | - | 136 (71.9) | - | ||
| 2 | 55 (24.2) | - | 47 (24.9) | - | ||
| > 3 | 6 (2.7) | - | 6 (3.2) | - | ||
PA-TACE: Postoperative adjuvant transcatheter arterial chemoembolization; BMI: Body mass index; BCLC: Barcelona Clinic Liver Cancer system; HBV: Hepatitis B virus; HCV: Hepatitis C virus; MVI: Microscopic vascular invasion; AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; NLR: Neutrophil-to-lymphocyte ratio; FHR: Ferritin-to-hemoglobin ratio; CRP: C-reactive protein.